Bcl-6
Inhibitory Selectivity
Bcl-6 Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S8250 |
79-6 (CID5721353)79-6 (CID5721353) (BCL6 inhibitor) is a BCL6 inhibitor with Kd value of 138 μM. |
||
| S8735 |
BI-3812BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM. |
||
| S8591 |
FX1FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis. |
||
| S6937New |
BI-3802BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor activity. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S8250 |
79-6 (CID5721353)79-6 (CID5721353) (BCL6 inhibitor) is a BCL6 inhibitor with Kd value of 138 μM. |
||
| S8735 |
BI-3812BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM. |
||
| S8591 |
FX1FX1 is a selective BCL6 BTB inhibitor with an IC50 value of 35 μM in reporter assays. FX1 shows great selectivity against a panel of 50 different kinases. 10 μM FX1 fails to significantly inhibit of any of these kinases. FX1 induces apoptosis. |
||
| S6937New |
BI-3802BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor activity. |
